Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829686 · ClinicalTrials.gov registry record · NA
Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
A NA study, sponsored by 59th Medical Wing.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT00829686 is a NA study that has completed, run by 59th Medical Wing. The registered enrollment target is 31 participants.
The verdict
NCT00829686, a NA study, has completed, sponsored by 59th Medical Wing.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures. Patients will then be randomized to 1)no antibiotic or 2) bacterium double strength (DS) (800/160) two tablets per oral (PO) twice a day x 7 days. This is the dose recommended for treating skin and soft tissue infections. (Ellis et al. Current Opinion in Infectious Diseases. 18(6):496-501, December 2005) Patients will then return to the emergency room (ER) on days 3 and 7 for wound repacking and evaluation. The primary outcome is clinical cure of abscess at 7 days after incision and drainage and recurrence rates within 30 days of treatment. Patients who are not improving at the following visit will then be treated with additional antibiotics or admission if needed. Data will be analyzed both by initial randomization and intention to treat. This serves as the pilot for the full placebo controlled randomized trial.
Interventions
- DRUG Septra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829686
The ClinicalTrials.gov registry entry for NCT00829686 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 59th Medical Wing, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Septra is the first listed.
NCT00829686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00829686 about?
NCT00829686 is a clinical study titled "Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection". Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures. Patients will then be randomized to 1)no antibiotic or 2) bacterium double strength (DS) (800/160...
What is the current status of trial NCT00829686?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2008-06. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00829686?
The interventions under investigation include: Septra (DRUG).
Who is sponsoring clinical trial NCT00829686?
This trial is sponsored by 59th Medical Wing, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.